Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 2/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21029380 | 0.90 | KIF11 (0.42) | MTNR1BKIF11HTR2ALTA4H | |
| SCHEMBL24899435 | 0.86 | MTNR1B (0.47) | MTNR1BCHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL6465672 | 0.81 | KIF11 (0.48) | MTNR1BKIF11 | |
| Hydrochloric Acid SCHEMBL6465670 | 0.81 | KIF11 (0.48) | MTNR1BKIF11 | |
| SCHEMBL5981452 | 0.80 | PSEN1 (0.40) | LTA4H | |
| SCHEMBL21029351 | 0.80 | TAAR1 (0.44) | MTNR1BKIF11LTA4H | |
| SCHEMBL19664068 | 0.80 | CTSS (0.49) | LTA4H | |
| SCHEMBL10561527 | 0.80 | CTSS (0.49) | LTA4H | |
| SCHEMBL30476035 | 0.80 | CTSS (0.49) | LTA4H | |
| SCHEMBL106531 | 0.78 | LDHA (0.53) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115766-B2 | Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORP. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040034246-A1 | Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-02-19 | — | — | US | disclosed |
| WO-2002044144-A2 | NUCLEOPHILIC APPROACH FOR PREPARING RADIOLABELED IMAGING AGENTS AND ASSOCIATED COMPOUNDS | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034246-A1 | Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds | SNCA, PARK7, SAMHD1 | MTNR1B 1881/4885KIF11 1832/4885CHRM2 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.